Balandrin; Manuel F.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Balandrin; Manuel F..The latest application filed is for "novel compounds advantageous in the treatment of central nervous system diseases and disorders".

Company Profile

0.13.10

Balandrin; Manuel F. - Sandy UT
Balandrin; Manuel F. - Salt Lake City UT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Novel Compounds Advantageous In The Treatment Of Central Nervous System Diseases And Disorders App 20210130285 - Pesyan; Amir ; et al.	2021-05-06
Compounds advantageous in the treatment of central nervous system diseases and disorders Grant 10,793,515 - Pesyan , et al. October 6, 2	2020-10-06
Novel Compounds Advantageous In The Treatment Of Central Nervous System Diseases And Disorders App 20160137592 - Pesyan; Amir ; et al.	2016-05-19
Compounds advantageous in the treatment of central nervous system diseases and disorders Grant 9,212,155 - Pesyan , et al. December 15, 2	2015-12-15
Calcium Receptor-active Molecules App 20130190407 - Van Wagenen; Bradford C. ; et al.	2013-07-25
Novel Compounds Advantageous In The Treatment Of Central Nervous System Diseases And Disorders App 20110046128 - Pesyan; Amir ; et al.	2011-02-24
Pyrimidinone Compounds As Calcilytics App 20070197555 - Shcherbakova; Irina V. ; et al.	2007-08-23
Calcium receptor-active molecules App 20060229470 - Van Wagenen; Bradford C. ; et al.	2006-10-12
Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases App 20060025477 - Artman; Linda D. ; et al.	2006-02-02
Inorganic ion receptor-active compounds Grant 6,710,088 - Moe , et al. March 23, 2	2004-03-23
Methods and compounds for treating depression and other disorders App 20040039014 - Mueller, Alan L. ; et al.	2004-02-26
Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses App 20030199589 - Balandrin, Manuel F. ; et al.	2003-10-23
Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses Grant 6,617,358 - Balandrin , et al. September 9, 2	2003-09-09
Inorganic ion receptor-active compounds App 20030008876 - Moe, Scott T. ; et al.	2003-01-09
Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID Grant 6,383,527 - Artman , et al. May 7, 2	2002-05-07
Inorganic ion receptor active compounds Grant 6,342,532 - Moe , et al. January 29, 2	2002-01-29
Calcium receptor-active molecules Grant 6,313,146 - Van Wagenen , et al. November 6, 2	2001-11-06
Calcium receptor-active compounds Grant 6,211,244 - Van Wagenen , et al. April 3, 2	2001-04-03
Calcium receptor-active molecules Grant 6,031,003 - Nemeth , et al. February 29, 2	2000-02-29
Calcium receptor-active molecules Grant 6,011,068 - Nemeth , et al. January 4, 2	2000-01-04
Calcium receptor-active molecules Grant 6,001,884 - Nemeth , et al. December 14, 1	1999-12-14
Inorganic ion receptor active compounds Grant 5,981,599 - Moe , et al. November 9, 1	1999-11-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.